Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (734 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painsubjectsneuropathicinjuryknee
  Phrases that lowered it: to investigatetrialdayvehiclerespiratory
• Sponsor's past termination rate: 10.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 5.6% (lowers risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 70.1% (lowers risk) · Drug's FDA history
• Disease area, neurology: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 39 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 11798 (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 302 (lowers risk) · Sponsor's track record
• Blinding: double (raises risk) · Design
• Drug's FAERS reports before start: 45409 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients NCT00654940 · started 2008 · scored riskier than 27% of active trials completed
• Efficacy and Safety of Pregabalin/Tramadol Combination Versus Pregabalin in Acute Pain of Neuropathic Origin NCT05324059 · started 2022 · scored riskier than 5% of active trials completed
• An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain NCT01202227 · started 2010 · scored riskier than 38% of active trials completed
• Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain NCT01455415 · started 2011 · scored riskier than 37% of active trials completed
• Study of Pregabalin in the Prevention of Central Neuropathic Pain in Acute Spinal Cord Injury NCT00879021 · started 2009 · scored riskier than 65% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.